Selecting the Optimal Architecture for Bi- and Multi-Specific Antibodies
02 Sept 2026
Formats & Scaffolds
- How do symmetric vs. asymmetric vs. fragment-based architectures trade off manufacturability, stability, and biological function?
- What antigen engagement requirements, simultaneous vs. sequential binding, valency, and epitope geometry should dictate scaffold choice?
- How do chain mispairing, aggregation, and immunogenicity profiles differ across common bispecific formats, and how can they be screened for early in the process?
- How should domain arrangement, linker length, and inter-domain flexibility be optimized for ternary complex formation in TCE design or conditional activation?
Industry Expert
